GlassScriptPhysician profile
Xiaoxiao Zhang
NPI 1356730089
$7,591.53
in general payments reported to CMS, 2019-2025
50 companies · $3,564 in 2025
The $3,564 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $569 · 2022: $1,309 · 2023: $610 · 2024: $1,540 · 2025: $3,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,405 · Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,405.02 |
| Education | $308.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $769.41 | 2022-2025 | Rybrevant, Darzalex, Carvykti |
| Incyte Corporation | $658.26 | 2021-2025 | Monjuvi, Jakafi, Niktimvo |
| Genzyme Corporation | $454.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $408.67 | 2022-2025 | Calquence, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $392.54 | 2022-2024 | |
| Genmab U.S., INC. | $365.68 | 2023-2025 | Epkinly |
| Novartis Pharmaceuticals Corporation | $286.77 | 2025 | |
| Syndax Pharmaceuticals, INC. | $283.77 | 2025 | Revuforj |
| Abbvie INC. | $278.00 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $262.43 | 2023-2025 | |
| Celgene Corporation | $250.69 | 2021-2024 | Pomalyst |
| Kite Pharma, INC. | $250.27 | 2022-2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $233.46 | 2022-2025 | Lynozyfic, Libtayo |
| Gilead Sciences, INC. | $225.03 | 2023-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $222.67 | 2025 | Welireg, Keytruda, Reblozyl |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $173.67 | 2024-2025 | Brukinsa, Tevimbra |
| Blueprint Medicines Corporation | $159.51 | 2022-2025 | Ayvakit |
| Emd Serono, INC. | $144.35 | 2024-2025 | |
| Taiho Oncology, INC. | $142.17 | 2024-2025 | |
| Astellas Pharma US INC | $140.40 | 2025 | Vyloy |
| Amgen INC. | $139.17 | 2025 | Imdelltra (Amg757) |
| Glaxosmithkline, LLC. | $130.88 | 2021-2025 | Ojjaara |
| Rigel Pharmaceuticals, INC. | $116.73 | 2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $104.51 | 2025 | Iclusig, Ninlaro |
| Seagen INC. | $103.13 | 2022 | |
| Pharmaessentia USA Corporation | $96.50 | 2025 | Besremi |
| Sobi, INC | $66.15 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $65.74 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $65.17 | 2024 | |
| Legend Biotech USA INC. | $59.85 | 2025 | Carvykti |
| Servier Pharmaceuticals LLC | $58.55 | 2025 | |
| Tersera Therapeutics LLC | $54.13 | 2024-2025 | Zoladex, Xermelo |
| Geron Corporation | $47.64 | 2025 | Rytelo |
| Exelixis INC. | $42.81 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $27.62 | 2025 | Enhertu |
| Eisai INC. | $25.78 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.52 | 2024 | Ultomiris |
| Sun Pharmaceutical Industries INC. | $23.25 | 2024 | |
| Beone Medicines USA, INC. | $23.20 | 2025 | Brukinsa |
| Stemline Therapeutics INC. | $22.64 | 2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $21.28 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $20.63 | 2025 | Tazverik |
| Pfizer INC. | $20.11 | 2025 | |
| Azurity Pharmaceuticals, INC. | $19.59 | 2025 | Danziten |
| Sumitomo Pharma America, INC. | $19.20 | 2024 | Orgovyx |
| Karyopharm Therapeutics INC. | $19.13 | 2025 | Xpovio |
| Cycle Pharmaceuticals INC | $18.77 | 2025 | Phyrago |
| Lilly USA, LLC | $18.69 | 2025 | Verzenio, Retevmo, Jaypirca |
| Acrotech Biopharma INC. | $18.32 | 2025 | Beleodaq |
| Puma Biotechnology, INC. | $15.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaoxiao Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.